Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128677 | 0.85 | MAOA (0.54) | CYP3A4TP53ALDH1A1MAP4K4RXRA | |
| SCHEMBL127074 | 0.83 | — | — | |
| SCHEMBL221178 | 0.83 | — | — | |
| SCHEMBL14744526 | 0.82 | CYP3A4 (0.48) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL8640357 | 0.80 | CYP3A4 (0.80) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL10975110 | 0.80 | CYP3A4 (0.93) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| Ammonia Solution, Strong SCHEMBL27616474 | 0.80 | CYP3A4 (0.80) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL4371942 | 0.80 | CYP3A4 (0.93) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL8640352 | 0.80 | CYP3A4 (0.80) | CYP3A4TP53ALDH1A1TSHRTHRB | |
| SCHEMBL30839724 | 0.80 | CYP3A4 (0.65) | CYP3A4TP53ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015454-A1 | HIGH PERFORMANCE, AMBIENT CURE POLYURETHANES COMPRISING POLYCAPROLACTONE POLYOLS | INGEVITY UK LTD (GB) | 2026-01-15 | — | — | US | claimed |
| EP-4594381-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | Ingevity UK Ltd (GB) | 2025-08-06 | — | — | EP | claimed |
| US-20250243313-A1 | POLYCAPROLACTONE POLYOLS, ELASTOMERS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-31 | — | — | US | claimed |
| WO-2025149744-A1 | POLYCAPROLACTONE POLYOLS, POLYURETHANE DISPERSIONS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| US-20250230274-A1 | POLYCAPROLACTONE POLYOLS, POLYURETHANE DISPERSIONS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-17 | — | — | US | claimed |
| US-20240110002-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | INGEVITY UK LTD (GB) | 2024-04-04 | — | — | US | claimed |
| WO-2024068129-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | INGEVITY UK LTD. (GB) | 2024-04-04 | — | — | WO | claimed |
| US-20260015454-A1 | HIGH PERFORMANCE, AMBIENT CURE POLYURETHANES COMPRISING POLYCAPROLACTONE POLYOLS | INGEVITY UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4594381-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | Ingevity UK Ltd (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243313-A1 | POLYCAPROLACTONE POLYOLS, ELASTOMERS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-31 | — | — | US | disclosed |
| US-20250230274-A1 | POLYCAPROLACTONE POLYOLS, POLYURETHANE DISPERSIONS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025149744-A1 | POLYCAPROLACTONE POLYOLS, POLYURETHANE DISPERSIONS, AND METHODS OF MAKING AND USING THE SAME | INGEVITY UK LTD (GB) | 2025-07-17 | — | — | WO | disclosed |
| US-20240110002-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | INGEVITY UK LTD (GB) | 2024-04-04 | — | — | US | disclosed |
| WO-2024068129-A1 | NOVEL POLYURETHANE OR POLYURETHANE-UREA COMPOSITION WITH ENHANCED LOW TEMPERATURE PERFORMANCE | INGEVITY UK LTD. (GB) | 2024-04-04 | — | — | WO | disclosed |
| US-20100286353-A1 | ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF | FUJIFILM CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100240908-A1 | ACETYLENE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2202221-A1 | ACETYLENE COMPOUND | Fujifilm Corporation (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240908-A1 | ACETYLENE COMPOUND | NAT1, KATNA1, KAT2B | CYP3A4 1909/4885TP53 4250/4885ALDH1A1 401/4885 |
| US-20260015454-A1 | HIGH PERFORMANCE, AMBIENT CURE POLYURETHANES COMPRISING POLYCAPROLACTONE POLYOLS | PUF60, MORF4L1, C9 | CYP3A4 1622/4885TP53 2114/4885ALDH1A1 538/4885 |
| US-20100286353-A1 | ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF | KAT8, HDAC10, SSRP1 | CYP3A4 3918/4885TP53 3212/4885ALDH1A1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.